Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of substituted olefin compound and its preparation method and application

A technology for compounds and uses, applied in the field of medicine, can solve the problems of poor drug characteristics and low efficacy

Active Publication Date: 2020-10-09
SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Fulvestrant is currently the only SERDs drug approved for clinical use, but its drug-forming properties are poor, it must be injected intramuscularly, and its efficacy is low. The dose of 500mg / month can only reach less than 50% of patients Degradation of estrogen receptors (Wardell, et al., Biochem.Pharm., 2011, 82:122-130)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of substituted olefin compound and its preparation method and application
  • A kind of substituted olefin compound and its preparation method and application
  • A kind of substituted olefin compound and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0179] Example 1: (E)-3-(4-((E)-2-(3-chloropyridin-4-yl)-1-(1H-indol-4-yl)-1-butenyl) Phenyl)acrylic acid (Compound 1)

[0180] Reaction route:

[0181]

[0182] The first step: N-acetyl-4-bromo-indole (compound 1-2)

[0183] Under nitrogen atmosphere, DMAP (122 mg, 1 mmol) was added to a suspension of 4-bromoindole (1.96 g, 10 mmol) in acetic anhydride (50 mL), and the reaction mixture was heated to about 140°C for about 3-4 hours. The reaction mixture was cooled to room temperature, poured into ice water, extracted with ethyl acetate, the organic phases were combined, washed with saturated aqueous sodium bicarbonate solution, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to obtain an oil Purified by column chromatography (PE:EA=10:1) to obtain N-acetyl-4-bromo-indole (2.2 g, yield 92%).

[0184] MS m / z(ESI):238[M+H] + .

[0185] The second step: N-acetyl-4-butynyl-indole (compound 1-4...

Embodiment 2

[0204] Example 2: (E)-3-(4-((Z)-2-(2-chlorophenyl)-1-(1H-indazol-5-yl)-1-butenyl)-3- Fluorophenyl)acrylic acid (Compound 2)

[0205] Reaction route:

[0206]

[0207]The first step: 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole

[0208] To a solution of 5-bromoindazole (1.97 g, 10 mmol) in dichloromethane (50 mL) under nitrogen atmosphere, were added 3,4-dihydro-2H-pyran (1.26 g, 15 mmol) and p-toluenesulfonic acid ( 194mg, 1mmol), the reaction mixture was reacted at room temperature for about 11-12h. Workup gave 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (2.52 g, yield: 90%).

[0209] MS m / z(ESI):281[M+H] + .

[0210] The second step: 5-(1-butynyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole

[0211] Under nitrogen atmosphere, to 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (2.5g, 8.9mmol) in N,N-dimethylacetamide (45mL) solution In, add cesium carbonate (5.8g, 17.8mmol), dppf (500mg, 0.9mmol), cuprous iodide (171mg, 0.9mmol), palladium acetate (200mg, 0.9...

Embodiment 3

[0232] Example 3: (E)-3-(4-((3E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indol-4-yl)-1-butenyl ) phenyl) acrylic acid (Compound 3)

[0233]

[0234] The first step: tert-butyl 4-bromo-1H-indolyl-1-carbonate

[0235] To a solution of 4-bromoindole (1.96g, 10mmol) in dichloromethane (50mL), DMAP (122mg, 1mmol) and di-tert-butyl dicarbonate (2.4g, 11mmol) were added, and the reaction system was stirred at room temperature for 8h, then Work-up gave tert-butyl 4-bromo-1H-indolyl-1-carbonate (2.96 g, 99% yield).

[0236] MS m / z(ESI):241[M-56+1] + .

[0237] The second step: tert-butyl 4-(1-butynyl)-1H-indole-1-carbonate

[0238] The operation is the same as the second step in Example 2, replacing 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole with 4-bromo-1H-indolyl-1 - tert-butyl carbonate to give tert-butyl 4-(1-butynyl)-1H-indole-1-carbonate (2.15 g, yield 80%).

[0239] MS m / z(ESI):214[M-56+1] + .

[0240] The third step: (Z)-4-(1,2-diboronic acid pinacol ester-1-butenyl)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a substituted olefin compound, and a preparation method and application thereof. Specifically, the application provides a substituted olefin compound, a stereoisomer, prodrug, solvate, and pharmaceutically acceptable salt or ester of the substituted olefin compound, a preparation method of the substituted olefin compound, and an application in preparing medicines for treating diseases relative to an excessive activity of estrogen receptors (such as ERalpha).

Description

technical field [0001] The present application relates to the field of medicine, specifically, the present application relates to a substituted olefinic compound and its preparation method and use; more specifically, the present application relates to compounds shown in formulas I-III in inhibiting estrogen receptor activity, Use in down-regulating the expression level of estrogen receptors or inducing the degradation of estrogen receptors; the application also relates to the use of compounds represented by formulas I-III in the preparation of drugs for preventing or treating diseases related to estrogen receptor overactivity Uses, especially estrogen receptor-positive (ER+) drug-resistant diseases (such as breast cancer that is resistant to anti-estrogen therapy, etc.). Background technique [0002] Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) are steroid hormone receptors and members of a large family of nuclear receptors. Both receptors are involved in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D401/06C07D231/56C07D209/08A61K31/4439A61K31/416A61K31/404A61P35/00A61P25/00A61P25/32A61P25/06A61P25/28A61P25/16A61P9/00A61P9/10A61P9/12A61P37/02A61P29/00A61P19/02A61P1/16A61P13/02A61P3/04A61P25/14A61P25/24A61P25/18A61P15/00A61P15/08A61P5/32
CPCC07D209/08C07D231/56C07D401/06
Inventor 刘钢于华董振文杜静王润江张园园曾宏宋宏梅葛勇王利春王晶翼
Owner SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com